Wonderful visit University of Arizona Health Sciences. Thank you Rachna Shroff, MD, FASCO and team at UA Cancer Center for hosting an outstanding symposium and panel discussion Nancy G. Brinker Susan G. Komen Need to expand community engagement to reduce disparities and improve outcomes for pts with cancer.

Pivotal phase 3 clinical trials with Dato-DXd ongoing, including Tropion-B03 enrolling pts with residual disease after neoadjuvant therapy for TNBC. Collaboration SWOG Cancer Research Network Kevin Kalinsky, MD, MS Eva M Ciruelos Dawn Hershman classic.clinicaltrials.gov/ct2/show/NCT05… #bcsm

Out in Journal of Clinical Oncology: Results from Tropion pan-tumor 01. In patients with advanced HR+ BC and TNBC, Dato-DXd (trop2 ADC) demonstrated promising clinical activity and a manageable safety profile. #bcsm @oncoalert Erika Hamilton, MD Full text: ascopubs.org/doi/pdf/10.120…

Excellent presentation at AACR by Rachel Occhiogrosso Abelman, MD on TOP1 mutations mediating cross-resistance to ADCs. Implications for ADC sequencing and drug development in MBC. #bcsm

Out in The Lancet the results of thePHERgain study showing impressive 3-y IDFS rate

A PET-based, pCR-adapted strategy could help identify patients with HER2-positive EBC who could safely omit chemotherapy

OncoAlert

thelancet.com/journals/lance…

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases | New England Journal of Medicine nejm.org/doi/full/10.10… Continued de-escalation of local therapies in breast cancer.

Thank you Jeffrey peppercorn MD for the advocacy and collaboration JCO Oncology Practice
Link to full text article: ascopubs.org/doi/10.1200/OP…

Anne dedicated the last decade of her life, living w MBC, to advocacy, & made an impact that will remain - & grow! - for years to come.

What an honor to have been by her side from the start of the Patient-Centered Dosing Initiative, & be leading it now.

therightdose.org/in-memoriam

The Right Dose: Patient Advocate–Led Survey out ⁦⁦JCO Oncology Practice⁩. Honoring PCDI’s founder Anne Loeser, for visionary leadership and commitment, this piece is a heartfelt tribute to her legacy following her passing from MBC ⁦Julia Maués⁩ #bcsm ascopubs.org/doi/10.1200/OP…

Powerful address by President Kelly K Hunt #SSO2024
📢 Empowering surgeons 💪🏻 goes through
✨Leadership
✨Mentorship: be a multiplier, not a diminisher
✨Collaboration: bring together pioneers, integrators, drivers & guardians
@mdandersonnews Sandra Wong @drcnclarke @tarikingmd

Thank you for the opportunity to present the #KEYNOTE756 data Society of Surgical Oncology! A potential future clinical practice change!! Stay tuned for the EFS update!! #SSO2024 #bcsm

One stop shop for #FDAOncology approval info organized by date (concise summary of approval, incl #clinicaltrials & key efficacy/safety results + link to label). Great resource for busy clinicians & #Hematology / #OncTwitter Boards prep. #regulatory #MedEd tinyurl.com/bdd5z46j

Fantastic think tank on #ADCs : spirited discussion on strategies to accelerate innovation and progress leveraging ADCs and bispecifics. Timely with recent FDA Oncology guidance on ADC development: fda.gov/media/155997/d…

Aditya Bardia, MD shares complexity of ADC seq w/pt who develops parallel subclonal alts conferring resistance to TROP2 in some and TOP1 in others
Coates, Sun et al Cancer Discovery 2021

📣Rachel Occhiogrosso Abelman, MD will present freq of TOP1/TROP2 mut and impact on cross-resistance AACR 2024

Great team effort to address an unmet need but more work needed to further improve outcomes for pts with MBC. Biomarker signal needs further refinement and validation in additional studies. #bcsm Hope Rugo Sara Tolaney Javier Cortes MD PhD Kevin Kalinsky, MD, MS Lisa Carey, MD, ScM, FASCO Journal of Clinical Oncology

U.S. FDA approval summary for elacestrant published on Journal of Clinical Oncology. Includes the rational for approval in the ESR1-mutant population.
ascopubs.org/doi/10.1200/JC…

NEW Breast Cancer Breakthroughs JAN 30! Learn how researchers are bringing new treatments to life that target an evolving breast tumor’s unique mutations from two experts, Komen scholar DonaldMcDonnell and former Komen grantee Aditya Bardia, MD. Info here: bit.ly/3X1yPW0

Join us tonight for #SABCSUpdate #1!

💬 Datopotamab Deruxtecan for HR+/HER2– Breast Cancer: Results From the Phase 3 TROPION-Breast01 Trial
👥 Aditya Bardia, MD, Marija Sullivan, & Megan E. Tesch
🕓 4:00 PM EST
📆 bit.ly/4a5bxX7

Dato-DXd for HR+ MBC:
Key takeaways:

PFS:
ESMO (BICR): 6.9 vs 4.9 months; HR 0.63; P <.0001
SABCS (Investigator): 6.9 vs 4.5 months; HR 0.64; P <.0001
OS: HR 0.84 (95% CI 0.62, 1.14)
ORR: 36.4% vs 22.9%

ESMO abstract: annalsofoncology.org/article/S0923-…
#SABCSUpdates

TROPION-PanTumor01
Efficacy and safety w/ Dato-DXd in P1 TROPION-PanTumor01

Heavily-pretreated HR+/HER2– BC (n=41):
mPFS 8.3 months
ORR 27%
DCR 85%

d27mnwjqm5ztsa.cloudfront.net/4d4d150a-bf20-…
#SABCSUpdates